Litigation Details for Apotex Inc v. Daiichi Sankyo, Inc. (N.D. Ill. 2015)
✉ Email this page to a colleague
Apotex Inc v. Daiichi Sankyo, Inc. (N.D. Ill. 2015)
Docket | ⤷ Try a Trial | Date Filed | 2015-04-27 |
Court | District Court, N.D. Illinois | Date Terminated | 2016-01-07 |
Cause | 15:1126 Patent Infringement | Assigned To | Sharon Johnson Coleman |
Jury Demand | None | Referred To | |
Patents | 6,878,703 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Apotex Inc v. Daiichi Sankyo, Inc.
Details for Apotex Inc v. Daiichi Sankyo, Inc. (N.D. Ill. 2015)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2015-04-27 | 1 | -infringement of United States Patent No. 6,878,703 (“the ’703 patent”) to enable Apotex to bring its…the expiration of United States Patent No. 5,616,599 (“the ’599 patent”) and any applicable pediatric … PATENT IN SUIT 15. On its face the ’703 patent entitled “Pharmaceutical…United States Patent and Trademark Office on April 12, 2005. A copy of the ’703 patent is attached as…States Patent and Trademark Office, Sankyo Company, Limited is the assignee of the ’703 patent. | External link to document | |
2016-01-07 | 66 | United States Patents Nos. 6,878,703 (the “703 patent”) and 5,616,599 (the “599 patent”) with the FDA…1) no patent information has been filed with the FDA, (2) the patent has expired, (3) the patent will …infringed the ‘599 patent, and Mylan’s Paragraph IV certifications for that patent were thus converted…ANDA infringed on a patent, and that it should not be considered until that patent expired). Mylan’s ANDAs…Paragraph IV certifications as to the ‘703 patent because that patent, although disclaimed, remains listed | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |